Pharmacogenetics to improve personalized antidepressant dosing in patients with severe depression; a randomized controlled trial using Tricyclic Antidepressants - Dosing of Tricyclic Antidepressants using Pharmacogenetics.

Radboud Universitair Medisch Centrum0 个研究点目标入组 250 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•Patients are in- and outpatients, having a primary diagnosis of severe major
•depressive disorder (SCID-I diagnosis in agreement with DSM-5 criteria and a
•Hamilton Rating Scale for Depression score * 19 (HRSD-17-item version), aged
•18-65 years, who, according to their physician, are eligible for treatment with
•a TCA (Nortriptyline (NOR), Clomipramine (CLOMI) or Imipramine (IMI)). The
•choice of the specific TCA is at the discretion of the physician in attendance.

•(1) Psychotic depression (2) Bipolar I or II disorder. (3) Schizophrenia or
•other primary psychotic disorder.(4) Drug or alcohol dependence in the past 3
•months. (5) Mental Retardation (IQ < 80). (6) For women: pregnancy or
•possibility for pregnancy without adequate contraceptive measures. (7)
•Breast-feeding. (8) Serious medical illness affecting the CNS, including but
•not restricted to M Parkinson, SLE, brain tumour, CVA. (9) Relevant medical
•illness as contra-indication for TCA use, such as recent myocardial infarction.
•(10) Other drugs influencing the pharmacokinetics of the TCAs as based on a
•list of interacting drugs. In case of psychotropic co-medication only a
•benzodiazepine in a dose equivalent up to 4 mg lorazepam will be allowed.

发起方